70% and CK-MB at 25%-30%; CK-BB is predominantly expressed in brain and smooth muscle, including vascular and uterine tissue. creatine kinase is a diagnostic biomarker in serum for myocardial infarct. 5 Roe et al use the zone electrophoresis method to identify and quantify the CK-MB in serum or plasma. The activity of enzyme in the serum or plasma was unstable and imprecise to respond to the actual level. Therefore, the measurement of CK-MB mass was applied, which was more sensitive and rapid than CK-MB activity assay.
And detection of CK-MB mass concentration is more suitable than determination of enzyme activity for AMI patients. 6 The chemiluminescence immunoassay is a commendatory method of detecting the concentration of enzyme.
In this study, the test kit detects the concentration of CK-MB by chemiluminescence immunoassay, a method what based on doubleantibody sandwich ELISA method has high specificity and sensitivity.
We evaluated the performance of CK-MB assay kit (chemiluminescence immunoassay Xiamen Innodx Biotech Co. Ltd) and compared to the commercial CK-MB assay kit (electro-chemiluminescence immunoassay, Roche).
| MATERIAL S AND ME THOD

| Clinical sample collection
All the samples, a total of 296 sample (143 patients, 153 healthy volunteers), were collected from the Xiamen University Affiliated Zhongshan Hospital, from December 2013 to April 2014. The serum or EDTA plasma samples were separated by centrifugation (3000 × g, 10 minutes) and stored at 4°C until used. All the information of samples were anonymous until the end of detection. 
| Reagents and instruments
| Reagents
| Method
All performance evaluation mainly referred to the "Guidelines for principle of analysis performance evaluation of in vitro diagnostic rea- 
| Linearity range
Series of calibration solution (L1-L8, concentration 0.1 ng/mL, 0.2 ng/mL, 0.8 ng/mL, 5 ng/mL, 20 ng/mL, 50 ng/mL, 250 ng/ mL, and 500 ng/mL) was detected in quadruplicate by test kit, and multiple regression models were selected to linearity analysis. All The linearity of measurements was evaluated by the t test of regression coefficient B3. As for linearity evaluation base on clinical criteria was judged by ADL (average deviation from linearity).
| Reportable range
Randomly selected a sample from samples had been quantified by Roche Cobas E170 and identified as low CK-MB concentration. Lowlevel samples (3.14 ng/mL) were diluted with 5% bovine serum albumin into 5 levels concentrations (recorded as Y1, Y2, Y3, Y4, and Y5 
| Recovery test
Three different CK-MB concentration samples were measured in triplicates (A1: high sample (83.17 ng/mL), A2: low sample (1.34 ng/ mL), A3:1/10 A1 mixed with 9/10 A2). The percentage ratio between the measured and estimated concentrations was calculated and acceptable range between 90 and 110%.
| Precision verification
High-level sample and low-level sample were detected by three different batch kits at the same time and repeat 20 times. Precision was evaluated as the coefficient of variation (CV), within-run and between-run imprecision CVs were obtained from the mean and standard deviation of data.
| Interference test
The effect of mild-hemolysis, hemoglobin, lipemia, bilirubin, and rheumatoid factor on the measurement of CK-MB in serum was assessed in vitro. Serum of normal samples was spiked with different concentrations of the interfering material. The relative bias of each determination was calculated between the before treatment and the after treatment. The maximum allowable relative bias was 15%.
| Cross-reactivity
Samples with CK-MM (14 000 ng/mL) and CK-BB (29 400 ng/mL) were selected to perform cross-reaction test. Test performance was carried by three different batches of test kit. The values of these tests were obtained and evaluated the cross-reactivity.
| Matrix effects
A sample was randomly selected, which had high CK-MB in serum, and diluted by kit diluent and serum matrix, respectively, for gradient dilution (0.1 ng/mL to 500 ng/mL). The RLU values of every test were recorded and evaluated the effect of diluent and matrix.
| Method comparison
A total of 296 anonymous serum samples from routine diagnostic testing were used to perform the method comparison study be- 
| Statistical analysis
The normal and the abnormal coincidence rates of comparison study were calculated as follows: normal coincidence rate (%) = a/ 
| RE SULTS
| Detection limit
The four parameters kit dose-response curve fitting was presented in Figure 1 . In study according to equation of kit dose-response curve 
| Linearity range
A scatter diagram ( Figure 2 ) was drawn with theoretical concentration (X-axis) and instrumental concentration (Y-axis). Then, the polynomial regression analysis was performed for first-, second-, and third-order polynomials. The result of t test for B3 presented that the data were not linear in statistical standard and then, the linearity of data was evaluated in clinical standard. The analysis of regression equation was shown in Table 1 , the average deviation from linearity (ADL) of second-and third-order regression equation was 0.1% and 1.1%, respectively. When the ADL<5%, the data were accepted as clinical linearity in the measuring range of 0.1 ng/mL ~ 500 ng/mL.
| Reportable range
The detection of low-level samples (3.14 ng/mL) and high-level samples (450 ng/mL) was depicted in Tables 2 and 3 . The CV% of the low-level samples (0.08 ng/mL-0.25 ng/mL) was less than 10% and detection limit was 0.1 ng/mL, so the minimum of reportable range was 0.1 ng/ mL. The high-level samples were diluted from 1:2 to 1:5, and the bias of 1:2 diluted sample test was minimum. And recommend maximum dilution ratio was 2. The maximum of reportable range = 2(recommend maximum dilution ratio) * 500 ng/mL (the upper limit of linearity range) =1000 ng/mL. The reportable range was from 0.1 ng/mL to 1000 ng/mL.
| Recovery test
The result of recovery test for three independent tests (A1, A2, and A3) was 106.83%, 92.94% and 100.02%, respectively, and within the acceptable range of 90% to 110%.
| Precision
The imprecision of CV was calculated as equation: CV % = SD/X × 100%. The test of precision for two different concentration samples was detected by three different batches of kit (Table 4 ).
The within-run and between-run imprecision CV values were both in an acceptable range <10%.
| Interference test
Those interference factors: hemoglobin, triglyceride, bilirubin, and rheumatoid factor that had several concentrations of were tested and the Bias% of every test was <±15% (Table 5 ). The result indicated that these common contaminants did not interfere with the test results of CK-MB.
| Cross-reactivity
Samples with isoenzymes of CK: CK-MM (14 000 ng/mL) and CK-BB (29 400 ng/mL) made no difference to the CK-MB value (Table 6 ). 
TA B L E 7 Results of the test kit and reference kit in clinical samples
| Matrix effect
There was no significant difference in CM-MB values between samples (P < .05), which were diluted by kit diluent and serum matrix, respectively, in the linearity range (Figure 3 ).
| Method comparison
The total coincidence rate of two methods was 93.24% (276/296), and the normal coincidence rate and abnormal coincidence rate were 92.16% (141/153) and 94.41% (135/143), respectively ( Table 7) .
Values of three samples were outside of detection limit of Roche kit and excluded the study of relevant analysis. And the regression 
| D ISCUSS I ON
CK-MB was as classical biomarkers of AMI. Although CK-MB is more concentrated in the myocardium, it also exists in skeletal muscle partly. And its elevations occur in a number of clinical diseases, including myocardial infarction, myopathy, and renal injury. 14 CK-MB first appears 4-6 hours after infarction onset, peaks at 24 hours, and returns to normal in 48-72 hours. 15 Its value in the early and late (>72 hours) diagnosis of AMI is limited. However, the release dynamics was helpful to diagnose reinfarction of AMI. There was a clear association between concentrations of enzyme and short-term clinical outcome, including risk of death, reinfarction, and emergency revascularization. 16 In this study, we evaluated the performance of the CM-MB assay (Innodox) and compared with the similar assay (Roche). The Innodox CK-MB assay kit was based on double antibodies sandwich ELISA.
The solid phase carrier of kit was nanometer magnetic particle; it could not only increase the reaction sensitivity but also greatly improves the anti-interference ability of the test. On the other hand, the assay used acridinium ester as chemiluminescent label has advantages of low background.
In this study, the performance evaluation was according to instructions from the "Guiding principles on performance analysis of diagnostic reagents in vitro." And the CLSI files were referred to for relevant standard procedures, too. The limit of determination was 0.1 ng/mL, better than Roche kit (0.3 ng/mL). And the report- In this comparison test, 2 commercial assay kits were chosen.
One is the Roche assay, which is an electro-chemiluminescence immunoassay. The other is the Abbott assay, which is used to confirm the comparison results. The Innodox kit had a great consistency with Roche kit, and total coincidence rate was 93.24%. Potential differences among the assays could be explained by the detection method used.
| CON CLUS ION
In conclusion, the evaluation of this kit demonstrated excellent diagnostic performance and fulfilled the requirement for clinical routine diagnosis. At the same time, Innodox kit was cheap than other commercial kits that was helpful for reducing the heavy burdens of patients.
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